Newsletter Tool

Today’s Big News

Jun 13, 2025

AstraZeneca pens $5.3B pact to use CSPC's AI platform to develop oral drugs for chronic diseases

BMS taps biotech analyst from Goldman Sachs to lead long-term strategy

The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble

Novo Nordisk plots phase 3 trials for next-gen obesity asset amycretin

Chutes & Ladders—Sanofi vaccine vet vaults to GSK

ADC Therapeutics shutters UK R&D site, culls several preclinical programs and trims workforce by 30%

Astellas offers lab space to startups to help Japanese biotechs 'go global'

Featured

AstraZeneca pens $5.3B pact to use CSPC's AI platform to develop oral drugs for chronic diseases

By James Waldron

AstraZeneca has returned to recent collaborator CSPC Pharmaceuticals with $110 million in upfront cash to start work on finding new oral drugs for a range of chronic diseases.

BMS taps biotech analyst from Goldman Sachs to lead long-term strategy

By Darren Incorvaia

Bristol Myers Squibb didn’t want to choose between clinical expertise and financial know-how when deciding on a new tactical leader. The Big Pharma has hired physician-turned-analyst Chris Shibutani, M.D., as executive vice president and chief strategy officer, BMS announced on June 9.

The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble

By James Waldron

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies.

Avoiding Costly Clinical Trial Delays Takes More Than Breaking Down Silos

Novo Nordisk plots phase 3 trials for next-gen obesity asset amycretin

By Gabrielle Masson

Wegovy-maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early next year.

Why Puerto Rico is the smart choice for bioscience reshoring

Chutes & Ladders—Sanofi vaccine vet vaults to GSK

By Darren Incorvaia,Zoey Becker

After 25 years developing vaccines with French drugmaker Sanofi, Sanjay Gurunathan, M.D., has departed for GSK. Gurunathan will head up the British Big Pharma’s vaccine and infectious disease R&D from Boston, working under Chief Scientific Officer Tony Wood, Ph.D.

ADC Therapeutics shutters UK R&D site, culls several preclinical programs and trims workforce by 30%

By Gabrielle Masson

After dropping its only clinical-stage candidate last month, ADC Therapeutics is shutting down a U.K. R&D site and laying off 30% of its workforce.

Astellas offers lab space to startups to help Japanese biotechs 'go global'

By James Waldron

Astellas Pharma will be inviting Japanese biotech startups to use its R&D lab as part of a government-backed acceleration program to help these companies “go global.”

AstraZeneca takes $181M hit in Syntimmune shareholder lawsuit on top of previous $130M award

By Kevin Dunleavy

For the second time in nine months, a Delaware judge has sided with Syntimmune shareholders over AstraZeneca, granting a $181 million award. The decision comes on top of a $130 million judgment issued in September of last year.

Democrats make pitch for Medicaid improvements as 'big beautiful bill' debate heats up

By Paige Minemyer

As the fight in the Senate over the "big beautiful bill" heats up, key Democrats have unveiled their own take on addressing fraud and waste in Medicaid.

UroGen's Zusduri wins FDA's blessing as first therapy for certain bladder cancer patients, despite negative adcomm vote

By Zoey Becker

Zusduri is the first approved therapy for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), standing to replace the current surgical standard-of-care.

Inside Fierce Medtech's Fierce 15

By Ayla Ellison,Conor Hale,Heather Landi

This week on "The Top Line," we unpack Fierce Medtech's Fierce 15 and spotlight startups reimagining healthcare.

Fierce Pharma Asia—Pfizer CEO talks bispecific deal; Otsuka's kidney disease win; Novartis-MSN Entresto feud

By Angus Liu

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. Otsuka detailed its phase 3 data in the kidney disease IgAN. Novartis is pressing for a speedy ruling in its Entresto patent litigation against MSN Pharmaceuticals.

Fierce podcasts